Syntagon introduces strategic pricing initiative

Leading contract research organisation, Syntagon, has unveiled a strategic pricing initiative that will see substantial cost savings for biotechnology and pharmaceutical customers taking compounds into phase I and phase II clinical trials.“Now, more than ever, customers are under growing pressure to make their limited resources stretch further. Cost-efficiency is increasingly critical; and maintaining cash is of utmost importance, especially for smaller companies,” says John Cameron, Director of Sales and Marketing at Syntagon. The initiative has been made possible by Syntagon’s decade-long